Profile: Albany Molecular Research Inc (AMRI.O)
1 Jul 2016
Albany Molecular Research, Inc., incorporated on August 6, 1998, is a global contract research and manufacturing company. The Company provides drug discovery, development, and manufacturing services. The Company operates through three segments: Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API) and Drug Product Manufacturing (DPM). The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small-scale commercial manufacturing. API includes pilot to commercial scale manufacturing of active pharmaceutical ingredients and intermediates and high potency and controlled substance manufacturing. DPM includes pre-formulation, formulation and process development through commercial scale production of complex liquid-filled and lyophilized injectable formulations. The Company supplies a range of services and technologies supporting the discovery and development of pharmaceutical products, the manufacturing of API and drug product for new and generic drugs, as well as research, development and manufacturing for the agrochemical and other industries.
The Company offers a portfolio of services from target identification tools to investigational new drug (IND) enabling activities. Its services and solutions consist of diverse chemistry library design and synthesis, medicinal chemistry, biology and pharmacology, including a suite of drug metabolism and pharmacokinetics that includes biotransformation and biocatalysis capabilities. The Company provides analytical chemistry and testing services for drug discovery, pharmaceutical development and manufacturing. Its Whitehouse Labs business offers an array of testing solutions, from materials and excipients; container qualification and container closure integrity testing; routine analytical chemistry; drug delivery systems and device qualification programs; packaging; distribution, and stability and storage programs. AMRI SSCI, LLC (SSCI) business provides capabilities in analytical services, a critical support function for pharmaceutical development, current good manufacturing practices (cGMP), API and drug product manufacturing.
The Company's manufacturing facilities are situated in various locations in the United States, Europe and Asia. These locations are integrated with the Company's pharmaceutical development services. Its locations provide customer solutions and enable the transfer of pre-clinical, clinical and commercial APIs from small-scale to large-scale production. It provides chemical synthesis and manufacturing services for its customers in accordance with cGMP regulations. Its API pipeline included approximately one product pending commercial launch, and approximately 63 additional APIs under development.
The Company provides facilities and solutions to deliver integrated pharmaceutical drug development programs and services, including process research and development, pre-formulation and formulation development, good laboratory practices (GLP) bioanalytical and separation sciences. It offers formulation development services for solid dosage, solution, suspension, topicals and injectables, cGMP early clinical phase capsules filling and cGMP early clinical powder in bottle for solution and suspension. It also provides cGMP contract manufacturing services in sterile syringe and vial filling using specialized technologies, including lyophilization. The Company provides its services for both small molecule drug products and biologicals, from small batch manufacturing to commercial scale.
Albany Molecular Research Inc
21 Corporate Cir,
PO Box 15098
ALBANY NY 12203-5154